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Abstract 
Introduction: Nitazoxanide has shown efficacy in vitro against coronavirus infections (MERS, SARS, SARS-CoV-2). The aim of this report is 
to describe the results of treating COVID-19 positive patients with nitazoxanide in three clinical settings: pregnancy/puerperium, hospitalized 
patients in an Internal Medicine Service and in an ambulatory setting. 
Methodology: This was a prospective follow-up and report of COVID-19 cases in three different situations, pregnant women, hospitalized 
patients receiving medical attention in an Internal Medicine Service and ambulatory patients residing in Toluca City, and Mexico City.  
Results: The experience with a first group of 20 women, pregnant (17) or in immediate puerperium (3) was successful in 18 cases with two 
unfortunate deaths. The five cases treated in an Internal Medicine service showed a positive outcome with two patients weaned from mechanical 
ventilation. Of the remaining 16 patients treated in an ambulatory setting, all got cured. Nitazoxanide seems to be useful against SARS-CoV-
2, not only in an early intervention but also in critical condition as well as in pregnancy without undesired effects for the babies. As an adjunctive 
therapy budesonide was used that seems to contribute to the clinical improvement. 
Conclusions: Nitazoxanide could be useful against COVID-19 as a safe and available regimen to be tested in a massive way immediately. 
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Introduction 
The Coronavirus disease 2019 (COVID-19) caused 
by the Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2) has evolved into a global 
pandemic [1]. This disease shows a broad spectrum of 
illness, mostly mild but a small percentage with serious 
disease, sometimes requiring intensive treatment. The 
mortality in the serious illness subgroup is high [2] and 
gets even higher if the patients end up needing 
mechanical ventilation [3]. In such critical and 
desperate situations, physicians are faced with the 
challenge to take difficult decisions but always with the 
best interests of the patients in the fore [4,5]. 
Unfortunately, there is currently no widely accepted 
standard of care in the pharmacologic management of 
patients with COVID-19 [6] and repurposing of 
existing drugs [7] seems to be the only plausible option 
for the majority of the worldwide population with 
scarce resources. 
Just over five months after the emergence of this 
variety of beta-coronaviruses, four facts are relevant. 
Firstly, the high contagiousness with disaggregation of 
the family nucleus due to the death of one or more 
affected family members, especially those with risk 
factors and the unusual impact on morbidity and 
mortality on health personnel; taking into consideration 
that we are still in an ascending phase of infections in 
Mexico. Secondly, we are witnessing the crushing of 
the world's global economy with the greatest impact on 
countries that traditionally have weak economies, such 
as the majority, including ours. The third issue is that 
the vast majority of products that are being tested 
against COVID-19 are far away from being able to be 
used in most nations due to their low availability and 
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high cost; and finally, the lack of an effective vaccine 
makes it mandatory to expand the repertoir of therapies 
against this virus.  
Given the reasoning above, it is very valid to 
identify new therapeutic alternatives with drugs that 
have demonstrated antiviral activity in vitro [8], have a 
good safety profile, and cost-benefit analysis that 
justifies their use in large population in multiple age 
groups including pregnant women. Nitazoxanide 
(NTZ), a medicine used in Mexico for many years as an 
antiparasitic [9] with a very low cost and easily 
available throughout the territory, fits this profile. This 
medicine is within the basic schemes of drugs of several 
healthcare institutions and has an extensive safety 
record spanning decades.  
Another anti-parasitic drug, ivermectin, has 
recently proposed for use in patients with Covid-19, but 
has the drawback that it cannot be used in pregnant 
women or in children [10]. Thus, the fundamental 
objective of this report is to reposition NTZ as a valid 
option against SARS-CoV-2 with a role similar to that 
of oseltamivir against influenza. 
Nitazoxanide (NTZ), 2-(acetyloxy)-N-(5-nitro-2-
thiazolyl) benzamide, is a broad-spectrum anti-infective 
drug that markedly modulates the survival, growth, and 
proliferation of a range of extracellular and intracellular 
protozoa, helminths, anaerobic and microaerophilic 
bacteria, in addition to viruses [11]. Besides, NTZ has 
also been shown to have anti-inflammatory properties 
[12]. 
NTZ has demonstrated in vitro activity against 
other coronavirus such as SARS-CoV-1,SARS-CoV-2, 
MERS-CoV [13] and murine coronavirus [14]. Based 
on these multiple in vitro and animal data, it is thought 
that NTZ may also have in-vivo activity against SARS-
CoV-2. As a matter of fact, adverse effects associated 
with this drug have been investigated and are 
uncommon [15]. For instance, patients may experience 
discoloration of urine, diarrhea, dizziness, 
gastroesophageal reflux disease, skin rash, or urticaria 
and less than 1% may eperience more severe symptoms, 
including anorexia, flatulence, increased appetite, 
enlarged salivary glands and dizziness [16] 
Although the in vitro activity of NTZ against 
SARS-CoV-2 is encouraging, more data is clearly 
needed to determine its role in the management of 
COVID-19. Surprisingly, data is limited regarding the 
efficacy of NTZ against human coronavirus. There are 
several publications that posit activity against COVID-
19 either used alone [17] or combined with other drugs 
[12], but unfortunately its potential usefulness has been 
largely ignored. Here we present the experience with 
NTZ in three circumstances: in pregnant, acutely ill 
hospitalized and in ambulatory patients. 
 
Methodology 
This was a prospective follow-up and report of 
COVID-19 cases in three different situations, pregnant 
women seen at the “Mónica Pretelini Sáenz” Maternal-
Perinatal Hospital (HMPMPS), hospitalized patients 
receiving medical attention in the Internal Medicine 
Table 1. General characteristics of the three groups. 
Variable Pregnant women (N = 20) 
Hospitalized patients in an 
Internal Medicine Service  
(N = 5) 
Ambulatory patients  
(N = 16) 
BMI (kg/m2) 27.8 ± 5.1 32.5 ± 6.5 28.8 ± 4.1 
Dyspnea (%) 60 100 43.8 
Fever (%) 75 80 43.8 
Headache (%) 35 100 81.3 
Cough (%) 45 100 68.8 
Sore throat (%) 5 40 37.5 
Joint pain (%) 25 100 62.5 
Muscle pain (%) 25 80 62.5 
Thoracic pain (%) 0 20 31.3 
Nasal discharge (%) 10 0 50 
Conjunctivitis (%) 0 40 6.3 
Disgeusia/ageusia (%) 0 20 37.5 
Anosmia (%) 0 0 37.5 
MBP (mmHg) 89.2 ± 7.9 81.2 ± 3.6 89.3 ± 9.3 
Heart rate (beats per minute) 101.2 ± 21.6 75 ± 10 98.7 ± 23.8 
Respiratory rate (breaths per minute) 22.8 ± 2.8 24.2 ± 2 22.2 ± 3.1 
Temperature (°C) 37.7 ± 1.0 37.2 ± 1 37.9 ± 1.1 
O2 saturation (%) 87.4 ± 8.3 78.8 ± 2.7 87.9 ± 6.3 
MBP: Mean Blood Pressure. 
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Service of the “Dr. Nicolás San Juan” General Hospital 
(both the hospitals are affiliated to the Health Institute 
of the State of Mexico, (ISEM)) and ambulatory 
patients from two cities - Toluca City and Mexico City. 
All patients were positive for SARS-CoV-2 by 
quantitative RT-PCR (qRT-PCR) from the respiratory 
tract. The information regarding COVID-19 
symptomatology, anthropometric variables, blood 
pressure, comorbid conditions, the type of treatment 
were documented in an Excel sheet designed 
specifically for this report. 
The blood tests in the groups that were seen in the 
Hospital, were taken after a fasting period of eight hours 
at minimum and processed following the indications of 
the International Federation of Clinical Chemistry 
(IFCC). This was a zero-risk study and the consent form 
was waived as the information was obtained from 
clinical files during routine use. In all cases the 
anonymity of the patients was preserved. 
 
Results 
The experience with the first group of 20 women 
who were pregnant (17) or in immediate puerperium (3) 
is showed in Table 1. The mean age of the patients was 
of 25.5 ± 4.6 years old with an important variability in 
the hospital stay, being anywhere from 1 to 30 days. 
The time with COVID-19 symptomatology before 
arriving at our hospital was 2.5 days (range 1-7), one 
death occurred due to delay in medical care (the patient 
was with respiratory symptoms for almost one week 
before arriving to our Hospital). 
The cause to arrive at the Third Level medical 
attention was COVID-19 symptoms in half of the 
patients, obstetrical hemorrhage in three cases, 
preeclampsia in two cases and in one case: fetal 
tachycardia, cervicovaginitis, unfavorable cervix, 
preterm delivery and pelvic fetus presentation. 
In fact, in this group there were two deaths, in one 
case for unknown reasons the drug was not 
administered over one weekend, but in both deaths the 
Computed Tomography (CT) evidenced severe lung 
lesion (Figure 1). On an average, the most common 
presenting symptom in pregnant/puerperal patients 
were fever (75%), dyspnea (60%) and cough (45%). All 
patients were given oxygen support and empirical 
antibiotic treatment based on clarithromycin and 
levofloxacin. 
The obstetrical data in this patient series is as 
follows: mean gestations: 2.2 (range 1-5), vaginal 
deliveries: 0.5 (range 0-2), abortions: 0.3 (range 0-1), 
cesareans: 1.2 (range 0-3). Five women were still 
pregnant when they were discharged from the hospital, 
twelve babies were healthy and without any COVID-19 
symptoms, unfortunately, two babies lost their moms. 
There were three fetal loses due to: ectopic pregnancy, 
fetal death at 16 weeks of pregnancy and a postnatal 
death from prematurity complications. Remarkably, 
one of the successful pregnancies was a woman with 
Hodgkin lymphoma. 
Although most of the women had a normal BMI, 
there were two with obesity, registering 37.1 and 35.6 
each. Two patients presented with preeclampsia. 
Importantly, 30% of the pregnant women developed 
transitory diarrhea after beginning the NTZ, but not 
enough to stop the treatment.  
In the case of hospitalized patients, in this initial 
approach we prescribed the drug to only five patients, 
three males and two females (mean age 45.2 ± 13.5 
years old) as an off-label use while thinking about 
initiating a randomized trial. In this respect, the 
response was quite promising, with two patients (a man 
Table 2. Laboratory values of the pregnant women and hospitalized patient in an Internal Medicine Service. 
Variable Pregnant women (N = 20) 
Hospitalized patients in an Internal 
Medicine Service 
(N = 5) 
Hemoglobin (g/dL) 12.4 ± 2.4 14.5 ± 2.1 
Hematocrit (%) 36.4 ± 6.6 42.4 ± 6.9 
Leucocytes (cells/mm3) 10930.0 ± 5564.2 5484 ± 893 
Lymphocytes (cells/mm3) 1706.5 ± 1986.9 747 ± 286.3 
Platelets (cells/mm3) 202300 ± 65531.9 330599.8 ± 30778.3 
 
Figure 1. Thoracic computed tomography of one of patients that 
died. 
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and a woman) in mechanical ventilation who were able 
to be weaned off of ventilatory support after six days in 
both cases. They developed ventialtor associated 
pneumonia and were treated with levofloxacin. 
Patient characteristics in this group – two patients 
were obesity grade II (BMI 39.4), two were overweight. 
Other comorbid conditions were Type 2 Diabetes 
Mellitus (T2DM) and Chronic Obstructive Pulmonary 
Disease (COPD). All these hospitalized patients 
received enoxaparin and paracetamol.  
It calls to our attention that 100% of the patients 
referred dyspnea, headache, cough and joint pain, and 
80% had fever. Eight patients had overweight, four with 
obesity grade I, two with obesity grade II and only two 
had normal weight. 
In the third scenario with ambulatory patients, our 
first experience was with 16 patients (mean age 47.8 ± 
16.9), eight men and eight women. In this cohort, two 
patients had grade II obesity, four had grade I obesity, 
eight were overweight and only one case per gender had 
normal weight. The most frequent symptom was 
headache at 81.3% and the next joint and muscle pain 
at 62.5%. Comorbidities were two patients with T2DM 
and one with hypertension and COPD. 
 
Discussion 
The regular NTZ antiparasitic dose is 500 mg twice 
a day. The anti-viral dose however is different [18]. 
Previously, long-acting NTZ 600 mg was used twice 
daily for 5 days, in a study in patients with acute 
uncomplicated influenza with minor adverse effects 
[19] and shown to reduce the duration of symptoms. 
However, based on the pharmacokinetic of this drug 
[20], the dose used in this case series report has been of 
500 mg every 6 hours [18]. 
Interestingly, a previous review publication 
included only 64 pregnant women in the analysis of 13 
papers [21]; that is relatively few as in this initial 
approach, the set of patients started with 20 women, 
with a mortality of 10%.  
In order of frequency, the main symptoms reported 
by pregnant women were different from those reported 
by Huag et al. for general population: fever (69.2%), 
dyspnea (61.5%) and cough (46.2%) [22]. This 
difference might be attributed to the physiological 
changes during pregnancy that confuse women and 
probably the dyspnea is underestimated. 
As expected, pregnant women were more anemic 
than the patients hospitalized in an Internal Medicine 
Service. By contrast, the group in the Internal Medicine 
service had lymphopenia at half the level for the 
reference value of our population.  
The fact that in the Internal Medicine Service 100% 
of the patients had lymphopenia, which contrasts 
percentages reported by other groups, for example, 63% 
described by Huang [22], probably is telling that our 
patients were in a more critical condition when looking 
for in-hospital care.  
Another point to consider is the importance of the 
chest CT [23]. Due to the large number of cases of 
COVID-19 that overwhelms the diagnostic system in 
Mexico, it is not possible to delay treatment while 
waiting for a PCR result, and the tomographic image is 
of great help in making a decision.  
No less important than the early administration of 
NTZ is the addition of steroids in selected patients. 
100% of the hospitalized patients (pregnant women and 
those of the Internal Medicine Service) received 
Clexane (enoxaparin) 40 mg S.C. once daily. In the 
ambulatory group 13 (81.25%) patients received Zinc 
at a dose of 220 mg/day as a complementary treatment 
based for its immunomodulatory effects [24].  
The low mortality in this small clinical experience 
in relation to the national and international data can be 
explained in part due to the age of young adults. 
Another issue to be analyzed is the early intervention 




The author humbly suggests NTZ could be useful 
against COVID-19 as a safe and viable treatment option 
to be tested in a massive way immediately. Finally, 
authors question whether the treatment against COVID-
19 has always been with us, and if so, how many lives 
could have been saved with a more organized, inclusive 
and coordinated way to evaluate several schemes taking 
into account previous data against other coronavirus 
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